GD2 : A Phase I/II Dose Schedule Finding Study of CH14.18/CHO Continuous Infusion Combined with Subcutaneous Aldesleukin (IL-2) in Patients with Primary Refractory or Relapsed Neuroblastoma

Project Details

Short titleGD2 : A Phase I/II Dose Schedule Finding Study of CH14.18/CHO Continuous Infusion Combined with Subcutaneous Aldesleukin (IL-2) in Patients with Primary Refractory or Relapsed Neuroblastoma
StatusFinished
Effective start/end date1/05/12 → 30/04/18

Funding

  • SOLVING KIDS' CANCER
  • Cancer Research UK